Cavitary MAC Treatment Guidelines

Introduction to Cavitary MAC Treatment

The American Thoracic Society recommends a daily oral regimen consisting of azithromycin 250 mg daily, ethambutol 15 mg/kg daily, and rifampin 10 mg/kg daily for cavitary MAC pulmonary disease, with consideration of initial intravenous amikacin for 2 months 1, 2, 3

Cavitary disease requires daily therapy, and intermittent dosing should never be used due to the high risk of developing macrolide resistance and treatment failure, as stated by the American College of Chest Physicians 1, 2
The American Thoracic Society states that macrolide monotherapy should never be used due to rapid development of macrolide resistance, which renders future treatment extremely difficult 1, 2, 3

The Infectious Diseases Society of America recommends azithromycin 250 mg daily or clarithromycin 500-1,000 mg daily as part of the standard daily regimen for cavitary MAC treatment 1, 3
Ethambutol 15 mg/kg daily is recommended, with initial 2 months at 25 mg/kg daily no longer recommended, and monthly vision checks required for prolonged therapy, as stated by the American Thoracic Society 1, 3, 4, 5
Rifampin 10 mg/kg daily, with a maximum of 600 mg, is recommended, with an alternative of rifabutin 150-300 mg daily if drug interactions necessitate, as stated by the American College of Chest Physicians 1, 6, 3

The American Thoracic Society recommends adding intravenous amikacin for the first 2 months when cavitary disease is present, particularly if AFB smear-positive sputum, severe radiological findings, or systemic signs of illness are present 6, 1
Amikacin dosing should be 15 mg/kg daily, with a maximum of 1,000 mg, adjusted to achieve peak levels of 20-30 mg/mL and trough levels <5-10 mcg/mL, as stated by the American College of Chest Physicians 6, 7

The American Thoracic Society recommends continuing therapy until sputum cultures remain negative for 12 consecutive months while on treatment, with monthly sputum cultures obtained throughout treatment to assess response 1, 2, 3
Clinical improvement is expected within 3-6 months, and sputum conversion to negative is expected within 12 months, as stated by the American College of Chest Physicians 1, 2

A macrolide plus ethambutol alone should not be used for fibrocavitary disease due to the risk of macrolide resistance emergence, as stated by the Infectious Diseases Society of America 1, 2
Patients respond best to MAC treatment the first time they receive it, and it is critical to use the full recommended multidrug regimen initially rather than attempting inadequate therapy, as stated by the American Thoracic Society 1
Rifampin significantly reduces clarithromycin levels through CYP3A4 induction, and rifabutin may be preferred when protease inhibitors or other CYP3A4 substrates are used, as stated by the American College of Chest Physicians 3

An ECG should be performed before starting treatment, and liver function tests should be done at baseline, at 1 month, and then every 6 months, as stated by the American Thoracic Society 3
Vision monitoring should be done monthly for patients on ethambutol, especially at higher doses, as stated by the American College of Chest Physicians 4, 5

If sputum cultures remain positive after 6 months of appropriate therapy, investigation of medication adherence, drug intolerance, macrolide resistance, and anatomic limitations should be done, as stated by the American Thoracic Society 1
Expert consultation should be sought for patients with macrolide-resistant MAC, treatment intolerance, or failure to respond to standard therapy, as stated by the Infectious Diseases Society of America 1, 3